A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS).

Hamza HasanMatthew P DeekRyan PhillipsRobert F HobbsReem MalekNoura RadwanAna P KiessShirl DipasqualeJames HuangTerry CaldwellJessica LeitzelDanielle WendlerHao WangElizabeth ThompsonJonathan PowellSara DudleyCurtiland DevilleStephen C GrecoDaniel Y SongTheodore L DeWeeseMichael A GorinSteven P RoweSam DenmeadeMark MarkowskiEmmanuel S AntonarakisMichael A CarducciMario A EisenbergerMartin G PomperKenneth J PientaChanning J PallerPhuoc T Tran

Published in: BMC cancer (2020)

Clinicaltrials.gov. Identifier: NCT04037358. Date of Registration: July 30, 2019. Date of First Participant Enrolled: August 9, 2019. Date of Last Approved Amendment: October 16, 2019. Protocol Version: Version 5.

Keyphrases

phase ii
clinical trial
open label
psychometric properties
prostate cancer
randomized controlled trial
phase iii
double blind
placebo controlled
young adults
heavy metals